NCT01495338

A Comparison of the Safety and Comfort of AC-170

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Aciex Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and comfort of AC-170 compared to a placebo.

Conditions

• Normal Ocular Health

Interventions

Type	Name	Description
DRUG	AC-170 0.17%	1 drop in one eye at one timepoint
DRUG	AC-170 0.24% (Formulation 1)	1 drop in one eye at one timepoint
DRUG	AC-170 0.24% (Formulation 2)	1 drop in one eye at one timepoint
DRUG	Olopatadine hydrochloride 0.2%/Tears Naturale II	1 drop in one eye at one timepoint

Timeline

• Start date: 2011-12-01
• Primary completion: 2011-12-01
• Completion: 2011-12-01
• First posted: 2011-12-20
• Last updated: 2017-09-14

Locations

1 site across 1 country: United States